IDT Biologika purchases Gallant Custom Laboratories
Gallant Custom Laboratories is known as the only Canadian company that has received authorization from the Canadian Food Inspection Agency (CFIA) to produce vaccines for autogenous viruses and bacteria.
“With its strong scientific focus, in-house research and development and production of autogenous vaccines for the Canadian market, Gallant is an outstanding match for the IDT Group,” Dr. Ralf Pfirmann, IDT Biologika CEO, said. “With this second acquisition in North America within just a few months, IDT Biologika is highlighting its expanding commitment to meeting the vaccine manufacturing needs in these key international markets.”
Gallant’s customers are located throughout Canada. Its customer base includes people who offer vaccines to the poultry and livestock industry in the nation.
“Gallant is an important addition to the IDT Biologika family both for its proprietary research and development in bacterial and viral vaccines, and also for its thorough market expertise, customer relations and network within the Canadian livestock industry,” Andreas Kastenbauer, managing director of IDT Biologika, said. “Gallant also has important collaborations with renowned academic institutions in the field of animal health vaccines, a key strength that we will continue to expand in the future.”
The transaction is scheduled to close on Aug. 31, 2015.